Medicus Pharma (NASDAQ:MDCX) will ring the Nasdaq Opening Bell on January 22, marking its one-year Nasdaq anniversary.
The biotech company focuses on advancing novel therapeutics, including SkinJect for basal cell carcinoma ($2 billion market) and Teverelix for advanced prostate cancer ($6 billion market).
Since listing, Medicus has progressed Phase 2 programs and pursued strategic partnerships for late-stage development.
CEO Dr. Raza Bokhari highlighted the company’s focus on execution and shareholder support.
“Our emphasis since becoming a public company has been on execution,” the CEO told investors in a statement.
“We are advancing a focused portfolio of therapies, anchored by our Skinject Phase 2 program, which is approaching database lock and clinical data readout resulting in potential partnering opportunity. We very much value the continued support of our shareholders in assembling decision-grade clinical and regulatory packages in therapeutic indications with significant unmet medical needs.”